Quantcast
Last updated on April 17, 2014 at 1:21 EDT

Latest Intrexon Corporation Stories

2014-04-16 16:30:21

GERMANTOWN, Md., April 16, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced the appointment of James S. Turley to its Board of Directors, effective April 16. Mr. Turley will occupy the board seat vacated by Thomas Reed, Ph.D., Founder and Chief Science Officer of Intrexon. Dr. Reed will continue to serve as Chief Science Officer. http://photos.prnewswire.com/prnvar/20130919/NY83283LOGO Mr. Turley is the former Chairman and Chief...

2014-03-31 16:27:23

GERMANTOWN, Md., March 31, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced its 2013 annual and fourth quarter results for 2013. http://photos.prnewswire.com/prnvar/20130919/NY83283LOGO Annual Highlights Highlights for 2013 included: -- Completion of Intrexon's initial public offering which, after taking into effect the exercise of the underwriters' over-allotment option, resulted in net proceeds to the company of...

2014-03-27 08:27:43

Joint Venture to Generate High-Value Oil Products from Low-Cost Natural Gas SAN CARLOS, Calif., March 27, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced the formation of Intrexon Energy Partners (IEP), a joint venture with a select group of external investors, to optimize and scale-up Intrexon's gas-to-liquid (GTL) bioconversion platform for the production of fuels and lubricants. IEP's first target product is isobutanol for...

2014-03-26 08:28:41

PRINCETON, N.J., March 26, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today its financial results for the year ended December 31, 2013. Soligenix's revenues for the year ended were $3.2 million as compared to $3.1 million for...

2014-03-17 08:29:45

GERMANTOWN, Md., March 17, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced that Samuel Broder, M.D., most recently Chairman of Intrexon's Health Sector and former Director of the National Cancer Institute, has been named as Executive Vice President of Scientific and Public Affairs reporting to Chairman and Chief Executive Officer Randal J. Kirk. http://photos.prnewswire.com/prnvar/20130919/NY83283LOGO In the new role, Dr....

2014-03-13 16:23:53

Company Increases Bioproduction Capabilities and Capacity SAN CARLOS, Calif., March 13, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced that it has acquired state-of-the-art laboratory operations in Budapest, Hungary from Codexis, Inc., a developer of biocatalysts for the pharmaceutical and complex chemistry industries. http://photos.prnewswire.com/prnvar/20130919/NY83283LOGO The acquisition will expand Intrexon's strain and...

2014-03-12 08:30:52

Former Endo Health and Johnson & Johnson Executive to Join as Senior Vice President GERMANTOWN, Md., March 12, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced the appointment of Kelly Huang, Ph.D., most recently President of HealthTronics, Inc., a subsidiary of Endo Health Solutions, to head the Company's newly established Consumer Sector. Dr. Huang will join Intrexon effective March 17, reporting to Chairman and Chief Executive...

2014-03-11 08:30:55

GERMANTOWN, Md., March 11, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced that Krish Krishnan, Chief Operating Officer of Intrexon, will present at the Barclays Global Healthcare Conference on Wednesday, March 12, at 9:30 a.m. Eastern Time at the Loews Hotel in Miami, Florida. http://photos.prnewswire.com/prnvar/20130919/NY83283LOGO About Intrexon Corporation Intrexon Corporation (NYSE: XON) is a leader in synthetic biology...

2014-03-10 08:30:21

BRIDGEWATER, N.J. and GERMANTOWN, Md., March 10, 2014 /PRNewswire/ -- Amneal Pharmaceuticals LLC, the seventh largest generic drug manufacturer by volume in the U.S., and Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced the formation of an Exclusive Channel Collaboration (ECC) to develop an improved production process for a complex active pharmaceutical ingredient (API). The companies will continue to explore other similar opportunities for...

2014-03-07 08:25:50

GERMANTOWN, Md. and SAN DIEGO, March 7, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced that it has completed the acquisition of San Diego-based Medistem, Inc. (OTCQB: MEDS), a pioneer in the development of Endometrial Regenerative Cells ("ERC" or "ERCs"), universal donor adult-derived stem cells with properties uniquely suited for therapeutic use with Intrexon's existing suite of synthetic biology technologies. Upon integration of...